Dianthus Therapeutics (DNTH) Stock Forecast & Price Target

Compare

422 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DNTH Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Dianthus

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DNTH Stock 12 Month Forecast

Average Price Target

$123.77

▲(59.17% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Dianthus Therapeutics in the last 3 months. The average price target is $123.77 with a high forecast of $200.00 and a low forecast of $80.00. The average price target represents a 59.17% change from the last price of $77.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","108":"$108","201":"$201","61.5":"$61.5","154.5":"$154.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":123.77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$123.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,61.5,108,154.5,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.26,66.39384615384616,77.5276923076923,88.66153846153847,99.79538461538462,110.92923076923077,122.06307692307692,133.19692307692307,144.33076923076922,155.46461538461537,166.59846153846152,177.7323076923077,188.86615384615385,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.26,60.53,65.8,71.07,76.34,81.61,86.88,92.15,97.41999999999999,102.69,107.96,113.22999999999999,118.5,{"y":123.77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.26,57.16307692307692,59.066153846153846,60.96923076923077,62.87230769230769,64.77538461538461,66.67846153846153,68.58153846153846,70.48461538461538,72.3876923076923,74.29076923076923,76.19384615384615,78.09692307692308,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.98,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.21,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.18,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 58, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$123.77

Lowest Price Target$80.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sadia Rahman

Wells Fargo

Not Ranked

Wells Fargo

$135

Buy

73.61%

Upside

Initiated

03/19/26

Dianthus initiated with an Overweight at Wells FargoDianthus initiated with an Overweight at Wells Fargo

Myles Minter

William Blair

$80

Buy

2.88%

Upside

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Minerva Neurosciences (NASDAQ: NERV)

Laura Chico

Wedbush

$80→$103

Buy

32.46%

Upside

Reiterated

03/12/26

Dianthus price target raised to $80 from $55 at WedbushDianthus price target raised to $80 from $55 at Wedbush

Alex Thompson CFA

Stifel Nicolaus

$65→$120

Buy

54.32%

Upside

Reiterated

03/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanobiotix (NASDAQ: NBTX), ImageneBio (NASDAQ: IMA) and Dianthus Therapeutics (NASDAQ: DNTH)

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

03/10/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

William Maughan

Clear Street

$100→$130

Buy

67.18%

Upside

Reiterated

03/10/26

Dianthus price target raised to $130 from $100 at Clear StreetDianthus price target raised to $130 from $100 at Clear Street

Ryan Deschner

Raymond James

$63→$123

Buy

58.18%

Upside

Reiterated

03/10/26

Dianthus upgraded to Strong Buy from Outperform at Raymond JamesDianthus upgraded to Strong Buy from Outperform at Raymond James

Rami Katkhuda

LifeSci Capital

$125

Buy

60.75%

Upside

Reiterated

03/09/26

Analysts' Top Healthcare Picks: Dianthus Therapeutics (DNTH), CalciMedica (CALC)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH), Myomo (NYSE MKT: MYO) and Hims & Hers Health (NYSE: HIMS)

Yatin Suneja

Guggenheim

$200

Buy

157.20%

Upside

Reiterated

03/09/26

Guggenheim Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)

Swayampakula Ramakanth

H.C. Wainwright

$47→$130

Buy

67.18%

Upside

Reiterated

03/09/26

Dianthus price target raised to $130 from $47 at H.C. WainwrightDianthus price target raised to $130 from $47 at H.C. Wainwright

Trevor Allred

Oppenheimer

$125→$145

Buy

86.47%

Upside

Reiterated

03/09/26

Dianthus price target raised to $145 from $125 at OppenheimerDianthus price target raised to $145 from $125 at Oppenheimer

Maury Raycroft

Jefferies

$81→$98

Buy

26.03%

Upside

Reiterated

03/09/26

Dianthus price target raised to $98 from $81 at JefferiesDianthus price target raised to $98 from $81 at Jefferies

Colleen M. Kusy

Robert W. Baird

$67→$132

Buy

69.75%

Upside

Reiterated

03/09/26

Dianthus price target raised to $132 from $67 at BairdDianthus price target raised to $132 from $67 at Baird

Gavin Clark-Gartner

Evercore ISI

$72→$88

Buy

13.17%

Upside

Reiterated

03/02/26

Dianthus Therapeutics (DNTH) Gets a Buy from Evercore ISI

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sadia Rahman

Wells Fargo

Not Ranked

Wells Fargo

$135

Buy

73.61%

Upside

Initiated

03/19/26

Dianthus initiated with an Overweight at Wells FargoDianthus initiated with an Overweight at Wells Fargo

Myles Minter

William Blair

$80

Buy

2.88%

Upside

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Minerva Neurosciences (NASDAQ: NERV)

Laura Chico

Wedbush

$80→$103

Buy

32.46%

Upside

Reiterated

03/12/26

Dianthus price target raised to $80 from $55 at WedbushDianthus price target raised to $80 from $55 at Wedbush

Alex Thompson CFA

Stifel Nicolaus

$65→$120

Buy

54.32%

Upside

Reiterated

03/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanobiotix (NASDAQ: NBTX), ImageneBio (NASDAQ: IMA) and Dianthus Therapeutics (NASDAQ: DNTH)

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

03/10/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

William Maughan

Clear Street

$100→$130

Buy

67.18%

Upside

Reiterated

03/10/26

Dianthus price target raised to $130 from $100 at Clear StreetDianthus price target raised to $130 from $100 at Clear Street

Ryan Deschner

Raymond James

$63→$123

Buy

58.18%

Upside

Reiterated

03/10/26

Dianthus upgraded to Strong Buy from Outperform at Raymond JamesDianthus upgraded to Strong Buy from Outperform at Raymond James

Rami Katkhuda

LifeSci Capital

$125

Buy

60.75%

Upside

Reiterated

03/09/26

Analysts' Top Healthcare Picks: Dianthus Therapeutics (DNTH), CalciMedica (CALC)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH), Myomo (NYSE MKT: MYO) and Hims & Hers Health (NYSE: HIMS)

Yatin Suneja

Guggenheim

$200

Buy

157.20%

Upside

Reiterated

03/09/26

Guggenheim Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)

Swayampakula Ramakanth

H.C. Wainwright

$47→$130

Buy

67.18%

Upside

Reiterated

03/09/26

Dianthus price target raised to $130 from $47 at H.C. WainwrightDianthus price target raised to $130 from $47 at H.C. Wainwright

Trevor Allred

Oppenheimer

$125→$145

Buy

86.47%

Upside

Reiterated

03/09/26

Dianthus price target raised to $145 from $125 at OppenheimerDianthus price target raised to $145 from $125 at Oppenheimer

Maury Raycroft

Jefferies

$81→$98

Buy

26.03%

Upside

Reiterated

03/09/26

Dianthus price target raised to $98 from $81 at JefferiesDianthus price target raised to $98 from $81 at Jefferies

Colleen M. Kusy

Robert W. Baird

$67→$132

Buy

69.75%

Upside

Reiterated

03/09/26

Dianthus price target raised to $132 from $67 at BairdDianthus price target raised to $132 from $67 at Baird

Gavin Clark-Gartner

Evercore ISI

$72→$88

Buy

13.17%

Upside

Reiterated

03/02/26

Dianthus Therapeutics (DNTH) Gets a Buy from Evercore ISI

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dianthus Therapeutics

3 Months

xxx

Success Rate

6/6 ratings generated profit

Average Return

+62.00%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +62.00% per trade.

1 Year

Gavin Clark-GartnerEvercore ISI

Success Rate

6/6 ratings generated profit

Average Return

+167.80%

reiterated a buy rating 21 days ago

Copying Gavin Clark-Gartner's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +167.80% per trade.

2 Years

xxx

Success Rate

6/6 ratings generated profit

Average Return

+167.80%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +167.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNTH Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DNTH has received 29 Buy Ratings, 58 Hold Ratings, and 0 Sell Ratings. DNTH average Analyst price target in the past 3 months is 123.77.

Each month's total comprises the sum of three months' worth of ratings.

DNTH Financial Forecast

DNTH Earnings Forecast

Next quarter’s earnings estimate for DNTH is -$1.06 with a range of -$1.56 to -$0.63. The previous quarter’s EPS was -$1.43. DNTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year DNTH has Performed in-line its overall industry.

DNTH Sales Forecast

Next quarter’s sales forecast for DNTH is $414.00K with a range of $0.00 to $1.20M. The previous quarter’s sales results were $284.00K. DNTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year DNTH has Performed in-line its overall industry.

DNTH Stock Forecast FAQ

What is DNTH’s average 12-month price target, according to analysts?

Based on analyst ratings, Dianthus Therapeutics’s 12-month average price target is 123.77.

What is DNTH’s upside potential, based on the analysts’ average price target?

Dianthus Therapeutics has 59.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DNTH a Buy, Sell or Hold?

Dianthus Therapeutics has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Dianthus Therapeutics’s price target?

The average price target for Dianthus Therapeutics is 123.77. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $80.00. The average price target represents 59.17% Increase from the current price of $77.76.

What do analysts say about Dianthus Therapeutics?

Dianthus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of DNTH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Dianthus Therapeutics (DNTH) Stock Forecast & Price Target

DNTH Analyst Ratings

DNTH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dianthus Therapeutics

DNTH Analyst Recommendation Trends

DNTH Financial Forecast

DNTH Earnings Forecast

DNTH Sales Forecast

DNTH Stock Forecast FAQ

Detailed List of Analyst Forecasts